Ozempic and GLP-1 Medications: Complete Patient Guide

Introduction

Ozempic (semaglutide) and the broader class of GLP-1 receptor agonists have reshaped modern medicine, moving well beyond their original role in type 2 diabetes management. GLP-1, or glucagon-like peptide-1, is a hormone produced naturally in the gut after eating. It signals the pancreas to release insulin, tells the brain to reduce appetite, and slows gastric emptying. Semaglutide mimics this hormone with remarkable precision and a long half-life of approximately seven days, enabling once-weekly dosing.

Originally approved by the FDA in 2017 for type 2 diabetes (Ozempic, subcutaneous injection), semaglutide is now also approved as Wegovy (2.4 mg) for chronic weight management, and as Rybelsus (oral tablet) for glycemic control. As of March 2024, Wegovy gained additional FDA approval to reduce major adverse cardiovascular events (MACEs) in adults with obesity or overweight who have established cardiovascular disease, a historic expansion of the drug's label.

Globally, GLP-1 drugs became one of the most-searched medical topics of 2024 and 2025. Real-world data from HealthVerity Marketplace, covering more than 19 million patients, shows that roughly one in five adults with a confirmed type 2 diabetes diagnosis had an active GLP-1 prescription by mid-2024. This article provides an evidence-based, comprehensive guide to how GLP-1 receptor agonists work, what they treat, how they are used, and what the latest research reveals.

This article is for general informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting, stopping, or adjusting any medication.

Causes and Symptoms

What is GLP-1 and Why Does It Matter?

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the small intestine and colon in response to food intake. Its physiological effects are wide-ranging:

• Stimulates glucose-dependent insulin secretion from pancreatic beta cells.
• Suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output.
• Slows gastric emptying, reducing postprandial glucose spikes.
• Acts on hypothalamic appetite centers to reduce hunger and increase satiety.
• Exerts direct cardiovascular protective effects on the heart and blood vessels.
• Modulates reward circuits in the brain, potentially reducing cravings for food and addictive substances.

In people with type 2 diabetes, GLP-1 secretion is blunted and the response of beta cells to GLP-1 is impaired. This is sometimes called "incretin defect." Native GLP-1 itself has a half-life of only 1 to 2 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide overcomes this limitation through structural modifications: an albumin-binding fatty acid chain that extends its half-life to approximately 165 hours (about 7 days), enabling once-weekly subcutaneous injection or once-daily oral dosing.

Who Is at Risk of Metabolic Disease?

Non-modifiable risk factors

• Family history of type 2 diabetes or cardiovascular disease.
• Age over 45 years.
• Genetic predisposition to obesity (e.g., FTO gene variants).
• History of gestational diabetes.

Modifiable risk factors

• Overweight or obesity (BMI 27 kg/m2 or higher with comorbidities; BMI 30+ for obesity diagnosis).
• Physical inactivity and sedentary behavior.
• High-calorie, ultra-processed diet.
• Smoking and heavy alcohol consumption.
• Poorly controlled hypertension or dyslipidemia.

Brand Names and Approved Formulations

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg injection): FDA-approved for type 2 diabetes and cardiovascular risk reduction.
• Wegovy (semaglutide 2.4 mg injection): FDA-approved for chronic weight management and cardiovascular risk reduction (March 2024).
• Rybelsus (semaglutide 3 mg, 7 mg, 14 mg oral tablet): FDA-approved for type 2 diabetes glycemic control.
• Tirzepatide (Mounjaro/Zepbound): A dual GLP-1/GIP receptor agonist with comparable or superior efficacy in some trials, included in the broader GLP-1 class for comparison.

GLP-1 Drug Comparison: Semaglutide vs Tirzepatide

Diagnosis

Diagnosing the underlying conditions for which GLP-1 receptor agonists are prescribed involves standard clinical criteria.

Type 2 Diabetes Diagnostic Criteria (ADA 2025)

• Fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) on two occasions.
• 2-hour plasma glucose greater than or equal to 200 mg/dL during a 75 g oral glucose tolerance test (OGTT).
• HbA1c greater than or equal to 6.5% (48 mmol/mol) on two occasions.
• Random plasma glucose greater than or equal to 200 mg/dL with classic hyperglycemia symptoms.

Obesity Diagnostic Criteria

• Body Mass Index (BMI) 30 kg/m2 or higher: obesity (Class I-III based on severity).
• BMI 27 kg/m2 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea): qualifies for pharmacotherapy.

Cardiovascular Risk Assessment

• Established cardiovascular disease (prior MI, stroke, or peripheral arterial disease): high-priority population for GLP-1 therapy based on SELECT and SOUL trial eligibility criteria.
• Framingham Risk Score or ACC/AHA Pooled Cohort Equations: used to stratify 10-year cardiovascular risk.

Labs Recommended Before Starting GLP-1 Therapy

• HbA1c (baseline glycemic control).
• Fasting lipid panel (LDL, HDL, triglycerides).
• Kidney function (eGFR, creatinine): semaglutide does not require dose adjustment for mild-to-moderate CKD but monitoring is advised.
• Thyroid function (TSH): not routine, but important in patients with thyroid history.
• Calcitonin: considered in patients with personal or family history of medullary thyroid carcinoma (MTC).
• Liver function tests if MASH (metabolic dysfunction-associated steatohepatitis) is suspected.

Treatment

Dosing and Titration

Semaglutide is started at a low dose and titrated gradually over weeks to months to minimize gastrointestinal side effects. The standard escalation for Wegovy (obesity) is:

• Weeks 1-4: 0.25 mg subcutaneously once weekly.
• Weeks 5-8: 0.5 mg once weekly.
• Weeks 9-12: 1.0 mg once weekly.
• Weeks 13-16: 1.7 mg once weekly.
• Week 17 onward: 2.4 mg once weekly (maintenance dose).

For Ozempic (diabetes), the escalation reaches 0.5 mg, then 1 mg, and up to 2 mg if additional glycemic control is needed.

Clinical Trial Evidence

STEP 1 Trial (NEJM, 2021): The foundational phase 3 trial enrolling 1,961 adults with obesity. Over 68 weeks, participants on semaglutide 2.4 mg lost a mean of 14.9% of body weight versus 2.4% with placebo. Nearly two-thirds (63%) achieved at least 15% weight loss and over a third achieved at least 20%. (High-quality evidence)

STEP 4 Trial (JAMA, 2021): Demonstrated that discontinuing semaglutide leads to weight regain. Participants who switched to placebo after a 20-week run-in regained approximately two-thirds of their lost weight within 48 weeks, confirming that long-term therapy is required for sustained benefit. (High-quality evidence)

STEP UP Trial (ADA 2025, Phase IIIb): An investigational 7.2 mg dose of semaglutide achieved a mean weight loss of 21% over 72 weeks in 1,407 adults with obesity and without diabetes. Over 90% of participants achieved at least 5% weight loss, and one-third lost 25% or more of body weight. Only 3.3% discontinued due to adverse events, suggesting a tolerable safety profile even at higher doses. (Moderate evidence, pending full publication)

SELECT Trial (NEJM, 2023, FDA-label-expanding): Among 17,604 adults with obesity or overweight and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (non-fatal MI, non-fatal stroke, cardiovascular death) by 20% relative to placebo over a mean follow-up of 34 months. This led to FDA approval for cardiovascular risk reduction in March 2024. (High-quality evidence)

SOUL Trial (2025, EMA approval driver): In nearly 10,000 patients with type 2 diabetes at high cardiovascular risk, oral semaglutide reduced the composite endpoint of cardiovascular death, non-fatal MI, and non-fatal stroke by 14% versus placebo. The EMA approved semaglutide as the first stroke management therapy based in part on this data in September 2025. (High-quality evidence)

SUSTAIN-6 (NEJM, 2016): The original cardiovascular outcome trial for Ozempic in type 2 diabetes, showing a 26% relative risk reduction in MACEs with semaglutide 1 mg versus placebo. (High-quality evidence)

GLP-1 Therapy in Real-World Settings

Real-world adherence data from Prime Therapeutics (2024 cohort): 63% of patients initiating Wegovy or Zepbound remained on therapy at one year, an improvement from 40% in the 2023 cohort. However, long-term persistence remains challenging, with only 14% of Wegovy initiators still on therapy at three years. Patients who discontinued within the first three months lost only 3.6% of body weight on average, while those who continued for the full duration achieved results closer to clinical trial benchmarks.

Glycemic Control

In type 2 diabetes, semaglutide achieves clinically meaningful HbA1c reductions. In early FDA trials involving more than 9,300 participants (of whom over 5,700 received semaglutide), 73% of semaglutide-treated patients achieved HbA1c below 7% at week 30, compared to 28% of placebo-treated patients. (High-quality evidence)

Multisystem Impact

GLP-1 receptor agonists affect multiple organ systems beyond glucose regulation, making them among the most pleiotropic drug classes in modern medicine.

Cardiovascular System

Semaglutide reduces blood pressure (systolic by approximately 3-5 mmHg on average), improves lipid profiles (reduces triglycerides and LDL modestly), and exerts direct anti-inflammatory and anti-atherosclerotic effects on vascular endothelium. The SELECT and SOUL trials confirm meaningful cardiovascular event reduction in high-risk populations. (High-quality evidence)

Kidneys

Observational data from real-world databases show that semaglutide is associated with lower rates of chronic kidney disease progression. The FLOW trial (2024) with oral semaglutide showed a 24% reduction in the risk of kidney disease progression or cardiovascular death in patients with type 2 diabetes and CKD. (High-quality evidence)

Liver (MASH/NAFLD)

Semaglutide significantly reduces liver fat content and hepatic inflammation in patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The ESSENCE trial (Phase 3, 2024) demonstrated that semaglutide 2.4 mg led to MASH resolution without worsening fibrosis in 63% of patients versus 34% with placebo. The FDA granted Breakthrough Therapy Designation for this indication. (High-quality evidence)

Brain and Addiction

GLP-1 receptors are expressed throughout mesolimbic and mesocortical reward circuits. A 2024-2025 study analyzing over 503,000 patients with opioid use disorder and 817,000 with alcohol use disorder found that GLP-1 receptor agonists were associated with significantly lower rates of opioid overdose and alcohol intoxication. Multiple observational studies document reduced alcohol consumption and craving with semaglutide treatment. Clinical trials specifically testing semaglutide for alcohol use disorder and smoking cessation are underway. (Moderate evidence; large-scale RCT results pending)

Neurodegeneration

Early evidence suggests GLP-1 receptor agonists may be neuroprotective. Several ongoing trials are testing semaglutide in Parkinson's disease and early Alzheimer's disease. The EMA's September 2025 approval for stroke risk reduction, based on SOUL trial data, represents the first regulatory recognition of a neurological benefit. (Low-to-moderate evidence for neurodegeneration; moderate evidence for stroke risk)

Warning Signs

Seek emergency medical care immediately if you experience any of the following while taking a GLP-1 receptor agonist:

• Severe, persistent abdominal pain radiating to the back: possible acute pancreatitis.
• Rapid swelling of the face, lips, tongue, or throat: possible anaphylaxis or angioedema.
• Signs of severe hypoglycemia (when used with insulin or sulfonylureas): extreme shakiness, confusion, loss of consciousness.
• Rapid or irregular heartbeat with dizziness or fainting.
• Lumps or swelling in the neck, difficulty swallowing, hoarseness: possible thyroid tumor (rare but serious).
• Severe nausea, vomiting, and dehydration causing inability to keep fluids down.
• Signs of gallbladder disease: sudden intense right-upper-quadrant pain, fever, jaundice.

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple endocrine neoplasia syndrome type 2 (MEN2).
• Known hypersensitivity to semaglutide or any excipient.
• Pregnancy (animal studies show fetal harm; use effective contraception and discontinue at least 2 months before planned conception for Wegovy).

When to See a Doctor

Consult your physician before starting GLP-1 therapy and at the following points during treatment

• Before initiation: full metabolic workup (HbA1c, lipids, kidney function, thyroid history review).
• Within the first 4 weeks: if nausea, vomiting, or diarrhea are severe enough to limit fluid intake or daily function.
• At 3 months: if less than 5% body weight loss has been achieved (re-evaluate therapeutic strategy).
• Any time you notice a lump in the neck, hoarseness, or difficulty swallowing.
• If you are taking insulin or a sulfonylurea: dose adjustment is often required to prevent hypoglycemia.
• Before any surgical procedure: GLP-1 therapy may delay gastric emptying, increasing aspiration risk under anesthesia. Current guidelines recommend holding Wegovy for one week before elective surgery.
• If planning pregnancy: semaglutide should be discontinued at least 2 months before conception.
• After discontinuation: plan with your doctor to prevent weight regain (STEP 4 data shows most weight is regained within one year of stopping therapy).

In Israel, GLP-1 medications are available via prescription from an endocrinologist or internal medicine specialist. Coverage by health funds (Kupot Holim) varies by indication and BMI threshold. Emergency services: 101 (Magen David Adom) or 112 (EU-standard emergency line).

Practical Tips

Starting GLP-1 Therapy: Practical Advice

• Injection technique: subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites each week. Store pens refrigerated (2-8 degrees C); once in use, may be kept at room temperature up to 30 days (Ozempic) or 28 days (Wegovy).
• Take Rybelsus (oral) on an empty stomach with a small sip of water (no more than 120 mL) and wait at least 30 minutes before eating, drinking, or taking other medications.
• Manage nausea by eating smaller, lower-fat meals; avoiding lying down immediately after eating; staying well hydrated.
• Set realistic expectations: clinical trials show meaningful weight loss begins after 4-8 weeks, with the most significant changes between weeks 16-68. Stopping therapy leads to weight regain.
• Combine with lifestyle changes: GLP-1 therapy is most effective as an adjunct to a calorie-controlled diet and regular physical activity. Trials consistently paired medication with behavioral counseling.
• Monitor muscle mass: some of the weight lost on GLP-1 agents may include lean muscle mass. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) are recommended to preserve muscle.
• Track HbA1c and metabolic labs every 3-6 months in patients with type 2 diabetes.
• Alcohol: limit alcohol intake while on semaglutide. GLP-1 agents may reduce alcohol cravings, but alcohol can worsen nausea and affect blood sugar.
• Cost and access: Wegovy and Ozempic are expensive. Check whether your health fund covers the medication and whether a prior authorization process is required. Generic semaglutide is not yet available; compounded semaglutide (from compounding pharmacies) is legally permitted in some countries during drug shortage periods but carries quality risks.

Lifestyle Optimization Checklist

• Aim for 150 minutes per week of moderate aerobic activity (brisk walking, cycling, swimming).
• Prioritize sleep: poor sleep (under 7 hours) increases ghrelin and reduces GLP-1 response.
• Manage stress: chronic stress elevates cortisol, which promotes visceral fat accumulation.
• Screen for micronutrient deficiencies if weight loss exceeds 10% body weight: vitamin B12, vitamin D, iron, folate.

FAQ

How does Ozempic differ from Wegovy?

Both contain semaglutide, but the dose and approved indication differ. Ozempic (up to 2 mg) is approved for type 2 diabetes and cardiovascular risk reduction. Wegovy (2.4 mg) is approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, and since March 2024 also for cardiovascular risk reduction. Rybelsus is the oral formulation, available in 3 mg, 7 mg, and 14 mg tablets for type 2 diabetes only.

How much weight can I expect to lose on Ozempic or Wegovy?

In the landmark STEP 1 trial published in the New England Journal of Medicine, participants on semaglutide 2.4 mg (Wegovy) lost a mean of 14.9% of body weight over 68 weeks. Nearly two-thirds lost at least 15%, and over one-third achieved 20% or more weight loss. At the diabetes dose used in Ozempic trials, mean weight loss was lower, typically 4-6%. Individual results depend on baseline weight, adherence, diet, and physical activity. The investigational 7.2 mg dose (STEP UP, 2025 ADA) achieved a mean of 21% weight loss. Results are not guaranteed, and weight is typically regained after stopping therapy.

What are the most common side effects of semaglutide?

The most frequently reported side effects are gastrointestinal: nausea (reported by up to 44% of Wegovy users), vomiting, diarrhea, and constipation. These are generally mild to moderate and most pronounced during dose escalation, improving after 4-8 weeks on a stable dose. Serious but rare adverse events include acute pancreatitis (approximately 0.2 cases per 100 patient-years in STEP trials), gallbladder disease (including cholelithiasis), and a theoretical risk of medullary thyroid carcinoma (observed in rodents at supratherapeutic doses; not confirmed in humans at approved doses but a contraindication applies). Only 3.3% of participants in the STEP UP trial discontinued due to adverse events.

Can I take GLP-1 drugs if I do not have diabetes or obesity?

Off-label use of semaglutide for weight loss in people who do not meet the BMI threshold (BMI under 27 kg/m2) is not supported by current guidelines and carries risks without established benefit in this population. Insurance typically will not cover the medication for off-label use. Use outside approved indications should only be considered under direct physician supervision. The pancreatitis risk, though small in absolute terms, was documented even in non-diabetic GLP-1 users in a 2023 JAMA study.

Do I need to take Ozempic forever?

Evidence from the STEP 4 trial (JAMA, 2021) shows that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within the following 48 weeks. This indicates that, like other chronic disease medications (antihypertensives, statins), long-term or indefinite use is required for sustained benefit. Ongoing clinical trials are evaluating intermittent dosing strategies and treatment holidays, but no current evidence supports stopping therapy once metabolic goals are achieved.

Is there an oral version of semaglutide?

Yes. Rybelsus is an oral tablet containing semaglutide, approved for type 2 diabetes in doses of 3 mg, 7 mg, and 14 mg once daily. It must be taken on an empty stomach with a small sip of water (120 mL maximum), at least 30 minutes before the first food, drink, or other oral medication of the day. Bioavailability of oral semaglutide is approximately 0.4-1% (compared to near-100% for subcutaneous injection), which is why the oral dose is much higher and the regimen stricter. An oral formulation of semaglutide for obesity is currently in Phase 3 trials.

Can GLP-1 drugs help with alcohol or drug addiction?

Emerging evidence suggests yes, though this is not yet an approved indication. A large observational study of over 1.3 million patients found that GLP-1 receptor agonists were associated with significantly lower rates of opioid overdose and alcohol intoxication. Multiple smaller studies document reduced alcohol cravings and alcohol intake in patients on semaglutide. GLP-1 receptors are expressed in the brain's reward circuits (mesolimbic and mesocortical pathways), which may explain these effects. Multiple phase 2 and phase 3 clinical trials on alcohol use disorder and nicotine dependence are currently underway (2025). (Moderate evidence pending RCT confirmation)

Summary

GLP-1 receptor agonists, led by semaglutide (Ozempic/Wegovy), represent a paradigm shift in the treatment of type 2 diabetes, obesity, and cardiovascular disease. The breadth of evidence is impressive: high-quality data from the STEP program, SELECT trial, SOUL trial, and ESSENCE trial collectively demonstrate clinically meaningful and statistically robust benefits across weight loss (14-21%), cardiovascular event reduction (14-26% relative risk reduction), kidney disease progression, liver disease resolution, and potentially neurological protection.

Yet these medications are not a cure. They require long-term, often indefinite use to sustain benefits. Side effects, particularly gastrointestinal symptoms during dose escalation, affect a substantial proportion of users, though serious adverse events are rare at approved doses. Cost and access remain significant barriers globally, and prescriber oversight is essential to ensure appropriate candidate selection, monitoring, and management.

For patients who qualify, the evidence strongly supports GLP-1 therapy as part of an integrated strategy combining medication, dietary modification, regular physical activity, and ongoing medical supervision. The next chapter for this drug class is being written rapidly: higher doses, oral formulations, new indications in addiction and neurodegeneration, and combination strategies with GIP agonists are all active research frontiers as of 2025 and 2026.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. https://jamanetwork.com/journals/jama/fullarticle/2777886
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
4. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
5. StatPearls. Semaglutide. National Center for Biotechnology Information. Updated February 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/
6. Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated with GLP-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. https://doi.org/10.1001/jama.2023.19574
7. HealthVerity. GLP-1 trends 2025: real-world data, patient outcomes and future therapies. August 2025. https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies
8. Ajmal H, et al. Off-label Ozempic and pancreatitis: legitimate concern or overblown fear? Ann Med Surg. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12577794/
9. Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12389369/
10. STEP UP Trial Results. Phase IIIb. Presented at ADA Scientific Sessions, May 2025. https://www.appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes
11. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Taylor and Francis. 2022. https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2147326
12. Semaglutide from Bench to Bedside. PMC. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12642005/
13. NeurologyLive. Repositioning GLP-1 Drugs for Neurologic Disease. May 2026. https://www.neurologylive.com/view/repositioning-glp-1-drugs-neurologic-disease-evidence-advances-outlook

Key Takeaways

• Semaglutide (Ozempic/Wegovy/Rybelsus) is a GLP-1 receptor agonist originally developed for type 2 diabetes, now approved for obesity and cardiovascular risk reduction.
• The STEP 1 trial demonstrated a mean 14.9% body weight reduction over 68 weeks with semaglutide 2.4 mg vs 2.4% with placebo (high-quality evidence).
• The SELECT trial showed a 20% relative risk reduction in major cardiovascular events in non-diabetic obese patients; FDA expanded Wegovy's label for cardiovascular protection in March 2024.
• Long-term therapy is required: STEP 4 showed that stopping semaglutide leads to regain of approximately two-thirds of lost weight within 48 weeks.
• GI side effects (nausea, vomiting, diarrhea) are the most common adverse events, typically mild to moderate and most prominent during dose escalation.
• Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN2).
• Emerging evidence supports GLP-1 effects in kidney disease (FLOW trial), liver disease (MASH/ESSENCE trial), and addiction medicine.
• Real-world persistence remains a challenge: only 14% of Wegovy initiators remain on therapy at 3 years.

Medical Disclaimer

This article is intended for general informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting, stopping, or altering any treatment or medication. GLP-1 receptor agonists including semaglutide require a valid prescription and ongoing medical supervision. Individual results vary; the data cited reflects population-level averages from controlled clinical trials. In Israel: Magen David Adom emergency line 101. International emergency: 112.